Cytori Therapeutics (CYTX) Upgraded to “Sell” at ValuEngine

Cytori Therapeutics (NASDAQ:CYTX) was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued on Friday.

Other research analysts have also issued reports about the stock. Maxim Group set a $5.00 price target on shares of Cytori Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 13th. Zacks Investment Research upgraded shares of Cytori Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. Finally, B. Riley reiterated a “hold” rating on shares of Cytori Therapeutics in a research note on Tuesday, November 7th.

Cytori Therapeutics (NASDAQ CYTX) opened at $0.40 on Friday. The stock has a market cap of $13.95, a PE ratio of -0.44 and a beta of 3.21. Cytori Therapeutics has a 12 month low of $0.22 and a 12 month high of $2.13.

Cytori Therapeutics (NASDAQ:CYTX) last issued its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.02. The company had revenue of $1.77 million during the quarter, compared to analyst estimates of $2.04 million. Cytori Therapeutics had a negative net margin of 367.33% and a negative return on equity of 228.21%. During the same period last year, the business earned ($0.26) EPS. equities analysts expect that Cytori Therapeutics will post -0.62 EPS for the current year.

In related news, major shareholder Bank Sa Swissquote sold 100,000 shares of the stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $0.38, for a total transaction of $38,000.00. Following the sale, the insider now directly owns 5,496,655 shares of the company’s stock, valued at approximately $2,088,728.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.90% of the stock is owned by company insiders.

Hedge funds have recently made changes to their positions in the stock. Perkins Capital Management Inc. grew its position in Cytori Therapeutics by 134.0% during the 4th quarter. Perkins Capital Management Inc. now owns 2,136,041 shares of the biotechnology company’s stock valued at $644,000 after purchasing an additional 1,223,046 shares during the last quarter. Vanguard Group Inc. grew its position in Cytori Therapeutics by 81.9% during the 2nd quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock valued at $674,000 after purchasing an additional 275,653 shares during the last quarter. Finally, Sabby Management LLC grew its position in Cytori Therapeutics by 28.0% during the 2nd quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock valued at $1,789,000 after purchasing an additional 355,504 shares during the last quarter. 7.34% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Cytori Therapeutics (CYTX) Upgraded to “Sell” at ValuEngine” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://sportsperspectives.com/2018/02/02/cytori-therapeutics-cytx-upgraded-to-sell-at-valuengine.html.

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply